Drug Profile

VGT 1849A

Alternative Names: VGT-1849A

Latest Information Update: 14 Jan 2026

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Vanda Pharmaceuticals
Class Antineoplastics; Antisense oligonucleotides
Mechanism of Action Gene silencing; Janus kinase 1 inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

Yes - Polycythaemia vera
New Molecular Entity Yes

Highest Development Phases

Preclinical Haematological malignancies; Polycythaemia vera

Most Recent Events

12 Jun 2025 Pharmacodynamics data from preclinical studies in Haematological malignancies presented at the 30th Congress of the European Haematology Association (EHA-2025)
20 Dec 2024 Preclinical trials in Haematological malignancies in USA (unspecified route) before December 2024
20 Dec 2024 Preclinical trials in Polycythaemia vera in USA (unspecified route) before December 2024

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com